|
| Press Releases |
|
 |
|
| Monday, November 30, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, more info >> |
|
| Friday, August 28, 2020 |
|
|
Sino Biopharm Announces 2020 Interim Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2020 (the "review period"). more info >> |
|
| Thursday, May 28, 2020 |
|
|
Sino Biopharmaceutical Announces 2020 First Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period"). more info >> |
|
| Tuesday, May 26, 2020 |
|
|
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug more info >> |
|
| Tuesday, May 19, 2020 |
|
|
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting |
| Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab more info >> |
|
| Monday, March 30, 2020 |
|
|
Sino Biopharm Announces 2019 Annual Results |
| Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX: 1177), a leading, innovative research and development driven pharmaceutical conglomerate in the PRC, has announced its financial results for the year ended 31 December 2019 ("the year"). more info >> |
|
| Tuesday, January 21, 2020 |
|
|
Asia-Pacific has Record Year for Clinical Trials says Novotech CRO |
| Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment. more info >> |
|
| Tuesday, November 26, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 Third Quarterly Results |
| Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2019 ("the review period"). more info >> |
|
| Thursday, August 29, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 Interim Results |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced today its unaudited interim results for the six months ended 30 June 2019 (the "review period").
more info >> |
|
| Wednesday, May 22, 2019 |
|
|
Sino Biopharmaceutical Announces 2019 First Quarterly Results |
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2019 ("the review period").
more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
The Generation Essentials Group and Black Spade Acquisition II Co Complete Business Combination 
Jun 5, 2025 11:33 HKT/SGT
|
|
|
Global Communities Unite at centralwOrld as Thailand Steps Forward on Global LGBTQ+ Stage with Central Pattana's Pride For All
Jun 5, 2025 08:30 HKT/SGT
|
|
|
TF International Facilitates Hong Kong's Successful Issuance of First Central Asian Sovereign Bond
Jun 4, 2025 22:28 HKT/SGT
|
|
|
Alpha Growth plc: Alpha Alternative Assets Fund Update ("AAAF")
Jun 4, 2025 15:00 JST
|
|
|
MHI Thermal Systems Receives A' Design Awards
Jun 4, 2025 14:10 JST
|
|
|
CBL International Limited Announces Share Repurchase Program
Jun 4, 2025 12:00 HKT/SGT
|
|
|
Orange completes successful trial of Fujitsu 1FINITY optical transport solution
Jun 4, 2025 12:58 JST
|
|
|
LIMA'25 Wraps up with RM11 Billion in Deals and Record Global Participation
Jun 4, 2025 11:00 HKT/SGT
|
|
|
Revigorate Announces Japan Launch, Asia Office, and New Portugal HQ
Jun 4, 2025 08:00 HKT/SGT
|
|
|
Implementation of Measures to Enhance Our Corporate Value in Connection with Toyota Industries Corporation
Jun 3, 2025 19:54 JST
|
|
|
Toyota Group to Accelerate Collaboration Towards Transforming into a Mobility Company Through Privatization of Toyota Industries Corporation
Jun 3, 2025 19:16 JST
|
|
|
Fujitsu accelerates digital transformation of financial institutions with newly systematized business strategy
Jun 3, 2025 18:46 JST
|
|
|
Fintech Forward Set to Return to Bahrain and Gather the Most Influential Leaders in Finance at its Third Edition in October 2025
Jun 3, 2025 17:45 HKT/SGT
|
|
|
Traditional Chinese Medicine Consumption Shows Promising Outlook, with Neautus's Market Leadership Becoming Increasingly Evident
Jun 3, 2025 16:56 HKT/SGT
|
|
|
Shiv Khera's New Book "Live While You're Alive" Launched in Singapore
Jun 3, 2025 15:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
